Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Lorenzo Galluzzi; Guido Kroemer; Alexander Eggermont

doi:10.4161/21624011.2014.967147

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

Oncoimmunology. 2014 Dec 21;3(11):e967147. doi: 10.4161/21624011.2014.967147. eCollection 2014 Nov.

Authors

Lorenzo Galluzzi¹, Guido Kroemer², Alexander Eggermont³

Affiliations

¹ Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM, U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.
² INSERM, U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Center de Recherche des Cordeliers ; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
³ Gustave Roussy Cancer Campus ; Villejuif, France.

No abstract available

Keywords: CTLA4; CTLA4, cytotoxic T lymphocyte-associate protein 4; FDA, Food and Drug Administration; Keytruda™; PD-1; PDCD1/PD-1, programmed cell death 1; Yervoy™; ipilimumab; nivolumab.